4.5 Article

Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability

期刊

VACCINE
卷 32, 期 9, 页码 1113-1120

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2013.10.091

关键词

Streptococcus pneumoniae; Whole cell vaccine; cGMP production

资金

  1. Sao Paulo Research Foundation (FAPESP) [03/07447-9, 08/10364-1]
  2. Butantan Foundation
  3. PATH
  4. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [08/10364-1] Funding Source: FAPESP

向作者/读者索取更多资源

Pneumococcal infections impose a large burden of disease on the human population, mainly in developing countries, and the current pneumococcal vaccines offer serotype-specific protection, but do not cover all pathogenic strains, leaving populations vulnerable to disease caused by non-vaccine serotypes. The pneumococcal whole cell vaccine is a low-cost strategy based on non-capsular antigens common to all strains, inducing serotype-independent immunity. Therefore, we developed the process for the cGMP production of this cellular vaccine. Initially, three engineering runs and two cGMP runs were performed in 60-L bioreactors, demonstrating the consistency of the production process, as evaluated by the growth curves, glucose consumption and metabolite formation (lactate and acetate). Cell recovery by tangential filtration was 92 +/- 13%. We optimized the conditions for beta-propiolactone (BPL) inactivation of the bacterial suspensions, establishing a maximum cell density of OD600 between 27 and 30, with a BPL concentration of 1:4000 (v/v) at 150 rpm and 4 degrees C for 30 h. BPL was hydrolyzed by heating for 2 h at 37 degrees C. The criteria and methods for quality control were defined using the engineering runs and the cGMP Lots passed all specifications. cGMP vaccine Lots displayed high potency, inducing between 80 and 90% survival in immunized mice when challenged with virulent pneumococci. Sera from mice immunized with the cGMP Lots recognized several pneumococcal proteins in the extract of encapsulated strains by Western blot. The cGMP whole cell antigen bulk and whole cell vaccine product lots were shown to be stable for up to 12 and 18 months, respectively, based upon survival assays following i.p. challenge. Our results show the consistency and stability of the cGMP whole cell pneumococcal vaccine lots and demonstrate the feasibility of production in a developing country setting. (C) 2013 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据